SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine presented positive initial Phase 2 data for DISC-3405 in…

Disc Medicine Inc · PRESS-RELEASE filed Sep 9, 2026 at 19:25 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Sep 9, 2026 at 19:25 ET

Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing significant phlebotomy reduction and hematocrit control. The company also provided an encore of positive Phase 2 RALLY-MF data for selcodebart in anemia of myelofibrosis. Both programs are advancing toward potential pivotal development, with an FDA end-of-Phase 2 meeting for selcodebart expected by year-end.

  • DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 per 26 weeks (p<0.0001) in PV patients.
  • 61.5% of patients remained phlebotomy-free post-baseline through 26 weeks.
  • Mean hematocrit maintained stably <45% through week 26.
  • DISC-3405 is the first anti-TMPRSS6 mAb to demonstrate phlebotomy reduction in PV patients.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access